Temozolomide-Associated Organizing Pneumonitis

Maldonado, Fabien; Limper, Andrew H.; Lim, Kaiser G.; Aubry, Marie-Christine
June 2007
Mayo Clinic Proceedings;Jun2007, Vol. 82 Issue 6, p771
Academic Journal
Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.


Related Articles

  • O6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Schold Jr., S. Clifford; Kokkinakis, Demetrius M.; Chang, Susan M.; Berger, Mitchel S.; Hess, Kenneth R.; Schiff, David; Robins, H. Ian; Mehta, Minesh P.; Fink, Karen L.; Davis, R. L.; Prados, Michael D. // Neuro-Oncology;Jan2004, Vol. 6 Issue 1, p28 

    The purpose of the study was to determine the dose of O6-benzylguanine (BG) that would suppress O6-alkylguanine- DNA alkyltransferase (AGT) activity to undetectable levels in >90% of anaplastic gliomas, as measured 6 h after a 1-h BG infusion. Subjects who were scheduled for surgical resection...

  • Temozolomide.  // Reactions Weekly;10/20/2012, Issue 1424, p47 

    The article describes the case of a 28-year-old man who developed Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome following temozolomide therapy for glioblastoma multiforme.

  • Bendamustine.  // Reactions Weekly;6/14/2012, Issue 1410, p12 

    The article describes the case of a 71-year-old female patient who experienced severe cytomegalovirus reactivation while undergoing bendamustine therapy.

  • Hydroxycarbamide.  // Reactions Weekly;7/9/2005, Issue 1059, p13 

    Discusses research being done on a male patient who developed acute myocardial infarction during his long-term treatment with hydroxycarbamide for sickle cell anemia. Reference to a study by A. Fattori et al published in a 2005 issue of the journal "Hematology"; Electrocardiogram results of the...

  • Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. Jeffrey Raizer // Journal of Neuro-Oncology;Jun2009, Vol. 93 Issue 2, p229 

    Abstract   Objective A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML). Background Alkylator-based chemotherapy is recognized to be leukemogenic; however, it is infrequently...

  • The Use of Alkylating Agents in the Treatment of Wegener's Granulomatosis. Hollander, Daniel; Manning, Robert T. // Annals of Internal Medicine;Aug67, Vol. 67 Issue 2, p393 

    Presents the case of a 30-year-old man with Wegener's granulomatosis which experienced therapeutic success with the use of alkylating agents. Medical history of the patient; Side effects reported in the patient's use of prednisone; Average survival time of Wegener's granulomatosis patients;...

  • Temozolomide.  // Reactions Weekly;1/12/2013, Issue 1434, p60 

    The article describes the cases of two patients with brainstem glioma and glioblastoma multiforme who developed maculopapular rash while receivinv temozolomide.

  • Temozolomide.  // Reactions Weekly;2/25/2012, Issue 1390, p38 

    The article describes the cases of 15 paediatric patients with diffuse intrinsic pontineglioma (DIPG), aged between 4 and 16 years, who developed various haematological and other toxicities during treatment with temozolomide.

  • Temozolomide.  // Reactions Weekly;2/25/2012, Issue 1390, p39 

    The article describes the case of a 62-year-old woman who developed cholestasis type liver injury while receiving temozolomide for glioblastoma and later died.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics